Isabelle Arnet

Dr. Isabelle Arnet

Department of Pharmaceutical Sciences, University of Basel, 4001 Basel, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2013 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
JMJulien Marquis
Julien Marquis
MSMarie P. Schneider
Marie P. Schneider
VPValérie Payot
Valérie Payot
ACAnne-Christine Cordonier
Anne-Christine Cordonier
OBOlivier Bugnon
Olivier Bugnon
Isabelle ArnetIsabelle Arnet
Isabelle Arnet

25 February 2016 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
Isabelle ArnetIsabelle Arnet
Isabelle Arnet
MKMarcel J. Kooij
Marcel J. Kooij
MMMarkus Messerli
Markus Messerli
KHKurt E. Hersberger
Kurt E. Hersberger
EHEibert Roelof Heerdink
Eibert Roelof Heerdink
MBMarcel Bouvy
Marcel Bouvy
Background: Medication adherence is the process by which patients take their medication as prescribed and is an umbrella term that encompasses all aspects of medication use patterns. Ambiguous terminology has emerged to describe a deviation from prescribed regimen, forcing the European ABC Project to define 3 phases of medication use: initiation, implementation, and discontinuation. However, different measures of medication adherence using medication records are currently available that do not always distinguish between these phases. The literature is lacking standardization and operationalization of the assessment methods. Objective: To propose a harmonization of standards as well as definitions of distinct measures and their operationalization to quantify adherence to medication from medication records. Methods: Group discussions and consensus process among all coauthors. The propositions were generated using the authors’ experiences and views in the field of adherence, informed by theory. Results: The concepts of adherence measures within the new taxonomy were harmonized, and the standards necessary for the operationalization of adherence measures from medication records are proposed. Besides percentages and time-to values, the addition of a dichotomous value for the reinitiation of treatment is proposed. Methodological issues are listed that should be disclosed in studies on adherence. Conclusions: The possible impact of the measures in adherence research is discussed. By doing this, the results of future adherence research should gain in accuracy. Finally, studies will become more transparent, enabling comparison between studies.

22 May 2022 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
LDLachlan L. Dalli
Lachlan L. Dalli
MKMonique Kilkenny
Monique Kilkenny
Isabelle ArnetIsabelle Arnet
Isabelle Arnet
FSFrank Sanfilippo
Frank Sanfilippo
DCDoyle M. Cummings
Doyle M. Cummings
Dominique CadilhacDominique Cadilhac
Dominique Cadilhac
Although medication adherence is commonly measured in electronic datasets using the proportion of days covered (PDC), no standardized approach is used to calculate and report this measure. We conducted a scoping review to understand the approaches taken to calculate and report the PDC for cardiovascular medicines to develop improved guidance for researchers using this measure. After prespecifying methods in a registered protocol, we searched Ovid Medline, Embase, Scopus, CINAHL Plus and grey literature (1 July 2012 to 14 December 2020) for articles containing the terms “proportion of days covered” and “cardiovascular medicine”, or synonyms and subject headings. Of the 523 articles identified, 316 were reviewed in full and 76 were included (93% observational studies; 47% from the USA; 2 grey literature articles). In 45 articles (59%), the PDC was measured from the first dispensing/claim date. Good adherence was defined as 80% PDC in 61 articles, 56% of which contained a rationale for selecting this threshold. The following parameters, important for deriving the PDC, were often not reported/unclear: switching (53%), early refills (45%), in‐hospital supplies (45%), presupply (28%) and survival (7%). Of the 46 articles where dosing information was unavailable, 59% reported how doses were imputed. To improve the transparent and systematic reporting of the PDC, we propose the TEN‐SPIDERS tool, covering the following PDC parameters: Threshold, Eligibility criteria, Numerator and denominator, Survival, Presupply, In‐hospital supplies, Dosing, Early Refills, and Switching. Use of this tool will standardize reporting of the PDC to facilitate reliable comparisons of medication adherence estimates between studies.

14 November 2016 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
SASamuel Allemann
Samuel Allemann
RNRobby Nieuwlaat
Robby Nieuwlaat
BBBart Van den Bemt
Bart Van den Bemt
Kurt E. HersbergerKurt E. Hersberger
Kurt E. Hersberger
Isabelle ArnetIsabelle Arnet
Isabelle Arnet
Introduction Despite much research, interventions to improve medication adherence report disappointing and inconsistent results. Tailored approaches that match interventions and patient determinants of non-adherence were seldom used in clinical trials. The presence of a multitude of theoretical frameworks and models to categorize interventions and patient determinants complicated the development of common categories shared by interventions and determinants. We retrieved potential interventions and patient determinants from published literature on medication adherence, matched them like locks and keys, and categorized them according to the Theoretical Domains Framework (TDF). Methods We identified the most relevant literature reviews on interventions and determinants in a pragmatic literature search, extracted all interventions and determinants, grouped similar concepts to umbrella terms and assigned them to TDF categories. All steps were finalized in consensus discussion between the authors. Results Sixteen articles (5 with determinants, 11 with interventions) were included for analysis. We extracted 103 interventions and 42 determinants that we divided in 26 modifiable and 16 unmodifiable determinants. All interventions and modifiable determinants were matched within 11 categories (Knowledge; Skills; Social/professional role and identity; Beliefs about capabilities; Beliefs about consequences; Intentions; Memory, Attention and decision processes; Environmental context and resources; Social influences; Emotion; and Behavioral regulation). Conclusion In published trials on medication adherence, the congruence between interventions and determinants can be assessed with matching interventions to determinants. To be successful, interventions in medication adherence should target current modifiable determinants and be tailored to the unmodifiable determinants. Modifiable and unmodifiable determinants need to be assessed at inclusion of intervention studies to identify the patients most in need of an adherence intervention. Our matched categories may be useful to develop interventions in trials that investigate the effectiveness of adherence interventions.

24 March 2014 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
FBFabienne Boeni
Fabienne Boeni
ESEsther Claire Spinatsch
Esther Claire Spinatsch
KSKatja Suter
Katja Suter
Kurt E. HersbergerKurt E. Hersberger
Kurt E. Hersberger
Isabelle ArnetIsabelle Arnet
Isabelle Arnet
This was a systematic review of the literature in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Evidence mapping was used to reveal the effect of drug reminder packaging on medication adherence, to identify research gaps and to make suggestions for future research.

29 November 2013 in International Journal of Clinical Pharmacy
Verified
Journal Article
Open access
PDF file
Isabelle ArnetIsabelle Arnet
Isabelle Arnet
IAIvo Abraham
Ivo Abraham
MMMarkus Messerli
Markus Messerli
KHKurt E. Hersberger
Kurt E. Hersberger
Background Several measures for calculating adherence to one medication from dispensing data records have been proposed, but the nomenclature is inconsistent and computations vary. The same measures, like the medication possession ratio (MPR), have been used for multiple medication regimens, and have tended to over- or under-estimate adherence rates. Objective To demonstrate the impact of varying elements in MPR to a single medication regimen; to define standards for the estimation of adherence to polypharmacy; to propose a new method for calculating adherence to polypharmacy; to face validate it. Setting Face validity of the proposed method. Method Variations in the MPR formula were simulated. Standards for the estimation of adherence to polypharmacy were defined. A new method to calculate adherence to polypharmacy was established. Its face validity with three illustrative cases obtained from a pharmacy refill database was assessed. Main outcome measure Adherence rate to polypharmacy from refill data records. Results MPR to a single medication is operationalized in the numerator and denominator and is influenced by the parameters like observation period, medication gaps, overlap. For polypharmacy, an average MPR is commonly used, which is not accounting for the specificity of multiple medications, and hence overestimating adherence rate. We propose the daily polypharmacy possession ratio (DPPR) as an index of adherence to polypharmacy. It estimates the proportion of time a patient had medication available for use by considering the presence or absence of multiple medications on each day in the observation period. We calculated possession rates from refill histories over 31 months (January 1, 2011–July 31, 2013) for three illustrative patients. The average MPR estimates were 80 % for a patient with 6 medications/20 refill dates, 90 % for a patient with 4 medications/11 refill dates, and 89 % for a patient with 3 medications/17 refill dates. The corresponding DPPRs were 75, 88 and 99 %, indicating overestimations by 5 and 2 %, and underestimation by 10 %, respectively. Conclusion The DPPR accounts for the specificity of polypharmacy including number of medications, medication switching, duplication, overlapping. Research is needed to further confirm the validity of this new index.